Please assess the completion status of the following clinical trial:

Trial Title: Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Obese (Body Mass Index or BMI greater than or equal to 30 kg/m2) women with PCOS between 18-40 years of age:~   * oligomenorrhea (less than 8 menstrual periods annually)~  * biochemical hyperandrogenemia (elevated total or free testosterone)~  * normal thyroid function tests and serum prolactin; AND~  * exclusion of 21a-hydroxylase deficiency by a fasting 17a-hydroxyprogesterone less than 200 ng/dl.51,~2. acceptable health on the basis of interview, medical history, physical examination, and laboratory tests (Complete Blood Chemistry or CBC, Comprehensive Metabolic Panel denoted SMA20, urinalysis, negative pregnancy test).~3. Signed, witnessed informed consent.~4. Ability to comply with study requirements.~Exclusion Criteria:~1. Diabetes mellitus by fasting glucose or oral glucose tolerance test (OGTT), or clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric, infectious, neoplastic and malignant disease (other than non-melanoma skin cancer).~2. Current use of oral contraceptives.~3. Documented or suspected recent (within one year) history of drug abuse or alcoholism.~4. Ingestion of any investigational drug within two months prior to study onset.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- 1/Pioglitazone (Type: EXPERIMENTAL): Pioglitazone in pill form at 45mg twice per day for 6 months
- 2/Placebo (Type: PLACEBO_COMPARATOR): Placebo control to arm 1 in pill form identical to treatment form also twice per day for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).